Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Ultragenyx Pharmaceutical Inc. (RARE) had Weighted-Average Shares Outstanding (Diluted) of 101.90M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$214.00M |
|
$-92.00M |
|
$34.00M |
|
$180.00M |
|
$289.00M |
|
$-75.00M |
|
$-16.00M |
|
$-91.00M |
|
$-91.00M |
|
$-92.00M |
|
$-92.00M |
|
$-92.00M |
|
$-92.00M |
|
$-75.00M |
|
$-67.00M |
|
101.90M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
101.90M |
$-0.90 |
|
$-0.90 |
|
| Balance Sheet Financials | |
$606.00M |
|
$235.00M |
|
$658.00M |
|
$1.26B |
|
$351.00M |
|
-- |
|
$1.20B |
|
$1.55B |
|
$-291.00M |
|
$-507.00M |
|
$-291.00M |
|
98.60M |
|
| Cash Flow Statement Financials | |
$-294.00M |
|
$-5.00M |
|
$3.00M |
|
$436.00M |
|
$140.00M |
|
$-296.00M |
|
$64.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.73 |
|
-- |
|
-- |
|
-- |
|
-- |
|
84.11% |
|
-35.05% |
|
-35.05% |
|
-- |
|
-42.52% |
|
-42.99% |
|
$-296.00M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
0.58 |
|
1.07 |
|
84.11 |
|
31.62% |
|
18.15% |
|
-7.28% |
|
31.62% |
|
$-2.95 |
|
$-2.90 |
|
$-2.89 |
|